CXCR2 antagonists

US8642643B2 · kind B2 · utility

Assignee

• Sanofi · FR

Inventors

• Stephanie Hachtel · Frankfurt am Main, DE
• Juergen Dedio · Frankfurt, DE
• Josef Pernerstorfer · Wuppertal, DE
• Stephen Shimshock · Fryeburg, US
• Carolina Lanter · Audubon, US
• Raymond W. Kosley, Jr. · Bound Brook, US

Key dates

• Filing date: Dec 18, 2008
• Grant date: Feb 4, 2014
• Expiry date: Jun 15, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07C2602/10
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to compounds of the formula Iin which R1, R2, A, B, X and Y have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.